Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE
Objective: to analyze the long term efficacy and tolerability of safinamide added as adjunctive therapy in a series of patients with Parkinson´s disease (PD) Background:…Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease
Objective: To compare Parkinson’s disease (PD) treatment practices by movement disorder (MD) specialists across a decade, and to determine the factors that influence drug choice…Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats
Objective: To investigate the effects of safinamide (saf) and rasagiline on in vivo glutamate (Glu) release in the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of Parkinson’s…Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)
Objective: We compared the effects of safinamide on the urinary symptoms of Parkinson's disease with other therapies. Background: Urinary symptoms (US) are common, disabling and…Is safinamide helpful in multiple system atrophy?
Objective: To retrospectively review the clinical benefit of safinamide in patients with Multiple System Atrophy. Background: Safinamide is a new monoamine oxidase-B inhibitor, with dopaminergic…Can Safinamide Help to Stabilize Dopaminergic Treatment in Parkinson’s Disease?
Objective: After more than two years of clinical experience with safinamide we want to retrospectively review its utility as a levodopa saver in our Parkinson's…Safinamide effect in patients with Parkinson’s disease and deep brain stimulation
Objective: Aim of this retrospective study is to evaluate safety and efficacy of safinamide in the treatment of motor complications in patients with Parkinson’s Disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.